Skip to main content
Top
Published in: Radiation Oncology 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child–Pugh grade B patients with locally advanced hepatocellular carcinoma

Authors: Jian-Xu Li, Rui-Jun Zhang, Mo-Qin Qiu, Liu-Ying Yan, Mei-Ling He, Mei-Ying Long, Jian-Hong Zhong, Hai-Yan Lu, Hong-Mei Zhou, Bang-De Xiang, Shi-Xiong Liang

Published in: Radiation Oncology | Issue 1/2023

Login to get access

Abstract

Background

The incidence of classic radiation-induced liver disease (cRILD) has been significantly reduced. However, non-classic radiation-induced liver disease (ncRILD) remains a major concern following radiotherapy in patients with hepatocellular carcinoma (HCC). This study evaluated the incidence of ncRILD following intensity-modulated radiotherapy (IMRT) for Child–Pugh grade B (CP-B) patients with locally advanced HCC and established a nomogram for predicting ncRILD probability.

Methods

Seventy-five CP-B patients with locally advanced HCC treated with IMRT between September 2014 and July 2021 were included. The max tumor size was 8.39 cm ± 5.06, and the median prescribed dose was 53.24 Gy ± 7.26. Treatment-related hepatotoxicity was evaluated within three months of completing IMRT. A nomogram model was formulated to predict the probability of ncRILD, using univariate and multivariate analysis.

Results

Among CP-B patients with locally advanced HCC, ncRILD occurred in 17 (22.7%) patients. Two patients (2.7%) exhibited a transaminase elevation of ≥ G3, fourteen (18.7%) exhibited a Child–Pugh score increase of ≥ 2, and one (1.3%) demonstrated both a transaminase elevation of ≥ G3 and a Child–Pugh score increase of ≥ 2. No cRILD cases were observed. A mean dose to the normal liver of ≥ 15.1 Gy was used as the cutoff for ncRILD. Multivariate analysis revealed that the prothrombin time before IMRT, tumour number, and mean dose to the normal liver were independent risk factors for ncRILD. The nomogram established on the basis of these risk factors displayed exceptional predictive performance (AUC = 0.800, 95% CI 0.674–0.926).

Conclusions

The incidence of ncRILD following IMRT for CP-B patients with locally advanced HCC was acceptable. A nomogram based on prothrombin time before IMRT, tumour number, and mean dose to the normal liver accurately predicted the probability of ncRILD in these patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
go back to reference Kanda T, Takahashi K, Nakamura M, Nakamoto S, Wu S, Haga Y, et al. Androgen receptor could be a potential therapeutic target in patients with advanced hepatocellular carcinoma. Cancers (Basel). 2017;9(5):43.CrossRefPubMedPubMedCentral Kanda T, Takahashi K, Nakamura M, Nakamoto S, Wu S, Haga Y, et al. Androgen receptor could be a potential therapeutic target in patients with advanced hepatocellular carcinoma. Cancers (Basel). 2017;9(5):43.CrossRefPubMedPubMedCentral
3.
go back to reference Stemmer SM, Manojlovic NS, Marinca MV, Petrov P, Cherciu N, Ganea D, et al. Namodenoson in advanced hepatocellular carcinoma and Child–Pugh B cirrhosis: randomized placebo-controlled clinical trial. Cancers (Basel). 2021;13(2):187.CrossRefPubMedPubMedCentral Stemmer SM, Manojlovic NS, Marinca MV, Petrov P, Cherciu N, Ganea D, et al. Namodenoson in advanced hepatocellular carcinoma and Child–Pugh B cirrhosis: randomized placebo-controlled clinical trial. Cancers (Basel). 2021;13(2):187.CrossRefPubMedPubMedCentral
4.
go back to reference Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child–Pugh–Turcotte class B cirrhosis. Lancet Oncol. 2017;18(2):e101–12.CrossRefPubMed Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child–Pugh–Turcotte class B cirrhosis. Lancet Oncol. 2017;18(2):e101–12.CrossRefPubMed
5.
go back to reference Feng M, Ben-Josef E. Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol. 2011;21(4):271–7.CrossRefPubMed Feng M, Ben-Josef E. Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol. 2011;21(4):271–7.CrossRefPubMed
6.
go back to reference Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Radiother Oncol. 2019;131:135–44.CrossRefPubMed Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Radiother Oncol. 2019;131:135–44.CrossRefPubMed
7.
go back to reference Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68(2):723–50.CrossRefPubMed Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68(2):723–50.CrossRefPubMed
8.
go back to reference Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys. 2010;78(4):1073–80.CrossRefPubMed Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys. 2010;78(4):1073–80.CrossRefPubMed
9.
go back to reference Munoz-Schuffenegger P, Ng S, Dawson LA. Radiation-induced liver toxicity. Semin Radiat Oncol. 2017;27(4):350–7.CrossRefPubMed Munoz-Schuffenegger P, Ng S, Dawson LA. Radiation-induced liver toxicity. Semin Radiat Oncol. 2017;27(4):350–7.CrossRefPubMed
10.
go back to reference Chapman TR, Bowen SR, Schaub SK, Yeung RH, Kwan SW, Park JO, et al. Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: defining clinically relevant endpoints. Pract Radiat Oncol. 2018;8(3):157–66.CrossRefPubMed Chapman TR, Bowen SR, Schaub SK, Yeung RH, Kwan SW, Park JO, et al. Toward consensus reporting of radiation-induced liver toxicity in the treatment of primary liver malignancies: defining clinically relevant endpoints. Pract Radiat Oncol. 2018;8(3):157–66.CrossRefPubMed
12.
go back to reference Bae SH, Park HC, Yoon WS, Yoon SM, Jung IH, Lee IJ, et al. Treatment outcome after fractionated conformal radiotherapy for hepatocellular carcinoma in patients with child–pugh classification B in Korea (KROG 16-05). Cancer Res Treat. 2019;51(4):1589–99.CrossRefPubMedPubMedCentral Bae SH, Park HC, Yoon WS, Yoon SM, Jung IH, Lee IJ, et al. Treatment outcome after fractionated conformal radiotherapy for hepatocellular carcinoma in patients with child–pugh classification B in Korea (KROG 16-05). Cancer Res Treat. 2019;51(4):1589–99.CrossRefPubMedPubMedCentral
13.
go back to reference Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child–Pugh B or C hepatocellular carcinoma. Radiother Oncol. 2014;111(3):412–7.CrossRefPubMed Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child–Pugh B or C hepatocellular carcinoma. Radiother Oncol. 2014;111(3):412–7.CrossRefPubMed
14.
go back to reference Jackson WC, Tang M, Maurino C, Mendiratta-Lala M, Parikh ND, Matuszak MM, et al. Individualized adaptive radiation therapy allows for safe treatment of hepatocellular carcinoma in patients with Child–Turcotte–Pugh B liver disease. Int J Radiat Oncol Biol Phys. 2021;109(1):212–9.CrossRefPubMed Jackson WC, Tang M, Maurino C, Mendiratta-Lala M, Parikh ND, Matuszak MM, et al. Individualized adaptive radiation therapy allows for safe treatment of hepatocellular carcinoma in patients with Child–Turcotte–Pugh B liver disease. Int J Radiat Oncol Biol Phys. 2021;109(1):212–9.CrossRefPubMed
15.
go back to reference Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682–720.CrossRefPubMedPubMedCentral Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682–720.CrossRefPubMedPubMedCentral
16.
go back to reference Yoon HI, Lee IJ, Han KH, Seong J. Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2014;140(9):1595–605.CrossRefPubMed Yoon HI, Lee IJ, Han KH, Seong J. Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2014;140(9):1595–605.CrossRefPubMed
17.
18.
go back to reference Ray P, Le Manach Y, Riou B, Houle TT. Statistical evaluation of a biomarker. Anesthesiology. 2010;112(4):1023–40.CrossRefPubMed Ray P, Le Manach Y, Riou B, Houle TT. Statistical evaluation of a biomarker. Anesthesiology. 2010;112(4):1023–40.CrossRefPubMed
19.
go back to reference Su TS, Luo R, Liang P, Cheng T, Zhou Y, Huang Y. A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma. Radiother Oncol. 2018;129(1):136–42.CrossRefPubMed Su TS, Luo R, Liang P, Cheng T, Zhou Y, Huang Y. A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma. Radiother Oncol. 2018;129(1):136–42.CrossRefPubMed
20.
go back to reference Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys. 2006;65(2):426–34.CrossRefPubMed Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys. 2006;65(2):426–34.CrossRefPubMed
21.
go back to reference Liang SX, Huang XB, Zhu XD, Zhang WD, Cai L, Huang HZ, et al. Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child–Pugh grade A cirrhosis. Radiother Oncol. 2011;98(2):265–9.CrossRefPubMed Liang SX, Huang XB, Zhu XD, Zhang WD, Cai L, Huang HZ, et al. Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child–Pugh grade A cirrhosis. Radiother Oncol. 2011;98(2):265–9.CrossRefPubMed
22.
go back to reference Velec M, Haddad CR, Craig T, Wang L, Lindsay P, Brierley J, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2017;97(5):939–46.CrossRefPubMed Velec M, Haddad CR, Craig T, Wang L, Lindsay P, Brierley J, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2017;97(5):939–46.CrossRefPubMed
23.
go back to reference McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, et al. Sorafenib as first-line therapy in patients with advanced Child–Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer. 2018;105:1–9.CrossRefPubMed McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, et al. Sorafenib as first-line therapy in patients with advanced Child–Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer. 2018;105:1–9.CrossRefPubMed
24.
go back to reference Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, et al. Observational registry of sorafenib use in clinical practice across Child–Pugh subgroups: the GIDEON study. J Hepatol. 2016;65(6):1140–7.CrossRefPubMed Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, et al. Observational registry of sorafenib use in clinical practice across Child–Pugh subgroups: the GIDEON study. J Hepatol. 2016;65(6):1140–7.CrossRefPubMed
25.
go back to reference Kim HD, Bang Y, Lee MA, Kim JW, Kim JH, Chon HJ, et al. Regorafenib in patients with advanced Child–Pugh B hepatocellular carcinoma: a multicentre retrospective study. Liver Int. 2020;40(10):2544–52.CrossRefPubMed Kim HD, Bang Y, Lee MA, Kim JW, Kim JH, Chon HJ, et al. Regorafenib in patients with advanced Child–Pugh B hepatocellular carcinoma: a multicentre retrospective study. Liver Int. 2020;40(10):2544–52.CrossRefPubMed
26.
go back to reference Lu J, Zhang XP, Zhong BY, Lau WY, Madoff DC, Davidson JC, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019;4(9):721–30.CrossRefPubMed Lu J, Zhang XP, Zhong BY, Lau WY, Madoff DC, Davidson JC, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019;4(9):721–30.CrossRefPubMed
27.
go back to reference Su F, Chen KH, Liang ZG, Wu CH, Li L, Qu S, et al. Comparison of three-dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus. Cancer Med. 2018;7(9):4387–95.CrossRefPubMedPubMedCentral Su F, Chen KH, Liang ZG, Wu CH, Li L, Qu S, et al. Comparison of three-dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus. Cancer Med. 2018;7(9):4387–95.CrossRefPubMedPubMedCentral
28.
go back to reference Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94-100.CrossRefPubMedPubMedCentral Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94-100.CrossRefPubMedPubMedCentral
29.
go back to reference Jun BG, Kim YD, Cheon GJ, Kim ES, Jwa E, Kim SG, et al. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma. Korean J Intern Med. 2018;33(6):1093–102.CrossRefPubMed Jun BG, Kim YD, Cheon GJ, Kim ES, Jwa E, Kim SG, et al. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma. Korean J Intern Med. 2018;33(6):1093–102.CrossRefPubMed
30.
go back to reference Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies–mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys. 2006;66(4):1152–8.CrossRefPubMed Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies–mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys. 2006;66(4):1152–8.CrossRefPubMed
31.
go back to reference Yoon HI, Koom WS, Lee IJ, Jeong K, Chung Y, Kim JK, et al. The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. Liver Int. 2012;32(7):1165–71.CrossRefPubMed Yoon HI, Koom WS, Lee IJ, Jeong K, Chung Y, Kim JK, et al. The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. Liver Int. 2012;32(7):1165–71.CrossRefPubMed
32.
go back to reference Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149(5):1226–39.CrossRefPubMed Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149(5):1226–39.CrossRefPubMed
Metadata
Title
Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child–Pugh grade B patients with locally advanced hepatocellular carcinoma
Authors
Jian-Xu Li
Rui-Jun Zhang
Mo-Qin Qiu
Liu-Ying Yan
Mei-Ling He
Mei-Ying Long
Jian-Hong Zhong
Hai-Yan Lu
Hong-Mei Zhou
Bang-De Xiang
Shi-Xiong Liang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2023
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-023-02232-5

Other articles of this Issue 1/2023

Radiation Oncology 1/2023 Go to the issue